$0.25
▲ +0.7% Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
Theriva Biologics: Q2 Earnings Snapshot
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Overview
52-week range
$0.16
$0.86
13% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
+0.9%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.07 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-0.05 | — | — | +96.8% | 0.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.45 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-1.93 | — | — | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-1.55 | — | — | — | +1.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-6.81 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-10.72 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-7.53 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-4.85 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.34 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.30 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $300,000 | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-3M | $-2M | — | $-4M | $-13M | $-4M | — | $-8M |
| Net income | $-3M | $-2M | — | $-4M | $-13M | $-4M | — | $-8M |
| EPS (diluted) | $-0.07 | $-0.05 | — | $-0.45 | $-1.93 | $-1.55 | — | $-6.81 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11M | $14M | $13M | $8M | $12M | $10M | $12M | $16M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $14M | $17M | $17M | $10M | $15M | $12M | $16M | $20M |
| Total assets | $35M | $38M | $38M | $31M | $36M | $32M | $35M | $40M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $23M | $23M | $23M | $24M | $25M | $17M | $16M | $15M |
| Total equity | $12M | $15M | $15M | $7M | $11M | $15M | — | $25M |
Implied volatility — last 90 days
No IV snapshots yet for TOVX.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.